The efficacy and safety of standardized allergen-removed Rhus verniciflua extract as maintenance therapy after first-line chemotherapy in patients with advanced non-small cell lung cancer

American Journal of Chinese Medicine

Volumn 41, Issue 4, 2013, Pages 773-787

  Lee, Jinsoo ^a   Chae, Jean ^a   Lee, Sookyung ^a   Kim, Kyungsuk ^a   Eo, Wankyu ^b   Kim, Sehyun ^a   Choi, Woncheol ^c   Cheon, Seong Ha ^a  

^a Kyung Hee University   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

^c Dankook University   (South Korea)

Author keywords

Advanced Non Small Cell Lung Cancer; Herbal Medicine; Maintenance Therapy; Standardized Allergen Removed Rhus verniciflua Stokes Extract

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CISPLATIN; CISPLATIN DERIVATIVE; CREATININE; GEMCITABINE; PEMETREXED; PLANT EXTRACT; RHUS VERNICIFLUA EXTRACT; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; INSOMNIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MALE; MEDICAL RECORD REVIEW; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; POISON IVY; PROGRESSION FREE SURVIVAL; RASH; RETROSPECTIVE STUDY; RHUS VERNICIFLUA; SIDE EFFECT; SKIN PRURITUS; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS; RETROSPECTIVE STUDIES; RHUS; TREATMENT OUTCOME;

EID: 84881153586     PISSN: 0192415X     EISSN: None     Source Type: Journal    
DOI: 10.1142/S0192415X13500523     Document Type: Article

References (51)

1. Behera, M., T.K. Owonikoko, Z. Chen, S.A. Kono, F.R. Khuri, C.P. Belani and S.S. Ramalingam. Single agent maintenance therapy for advanced stage non-small cell lung cancer: a metaanalysis. Lung Cancer 77: 331-338, 2012.
2. Brodowicz, T., M. Krzakowski, M. Zwitter, V. Tzekova, R. Ramlau, N. Ghilezan, T. Ciuleanu, B. Cucevic, K. Gyurkovits, E. Ulsperger, J. Jassem, M. Grgic, P. Saip, M. Szilasi, C. Wiltschke, M. Wagnerova, N. Oskina, V. Soldatenkova, C. Zielinski and M. Wenczl. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 52: 155-163, 2006.
3. Campiglio, M., R. Bufalino, M. Sandri, E. Ferri, R.A. Aiello, A. De Matteis, M. Mottolese, S. De Placido, P. Querzoli, A. Jirillo, A. Bottini, M. Fantini, A. Bonetti, F. Pedani, M. Mauri, A. Molino, A. Ferro, S.M. Pupa, M. Sasso, S. Menard, A. Balsari and E. Tagliabue. Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. Breast Cancer Res. Treat. 128: 147-154, 2011.
4. Cappuzzo, F., T. Ciuleanu, L. Stelmakh, S. Cicenas, A. Szczesna, E. Juhasz, E. Esteban, O. Molinier, W. Brugger, I. Melezinek, G. Klingelschmitt, B. Klughammer and G. Giaccone. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 11: 521-529, 2010.
5. Cheon, S.H., K.S. Kim, S. Kim, H.S. Jung, W.C. Choi and W.K. Eo. Efficacy and safety of Rhus verniciflua stokes extracts in patients with previously treated advanced non-small cell lung cancer. Forsch Komplementmed. 18: 77-83, 2011.
6. Chien, C.S., K.H. Shen, J.S. Huang, S.C. Ko and Y.W. Shih. Antimetastatic potential of fisetin involves inactivation of the PI3K/Akt and JNK signaling pathways with downregulation of MMP-2/9 expressions in prostate cancer PC-3 cells. Mol. Cell. Biochem. 333: 169-180, 2010.
7. Choi, W.C., H.J. Lee and E.O. Lee. Study on antiangiogenic and antitumor activities of processed Rhus verniciflua Stokes extract. Korean J. Oriental Physiol. Pathol. 20: 825-829, 2006.
8. Choi, W.C., H.S. Jung, K.S. Kim, S.K. Lee, S.W. Yoon, J.H. Park, S. Kim, S.H. Cheon and W.K. Eo. Rhus verniciflua stokes against advanced cancer: a perspective from the Korean Integrative Cancer Center. J. Biomed. Biotechnol. 2012: 874276, 2012.
9. Ciuleanu, T., T. Brodowicz, C. Zielinski, J.H. Kim, M. Krzakowski, E. Laack, Y.L. Wu, I. Bover, S. Begbie, V. Tzekova, B. Cucevic, J.R. Pereira, S.H. Yang, J. Madhavan, K.P. Sugarman, P. Peterson, W.J. John, K. Krejcy and C.P. Belani. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374: 1432-1440, 2009.
10. Cohen, M.H., P. Cortazar, R. Justice and R. Pazdur. Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC). Oncologist 15: 1352-1358, 2010a.
11. Cohen, M.H., J.R. Johnson, S. Chattopadhyay, S. Tang, R. Justice, R. Sridhara and R. Pazdur. Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC). Oncologist 15: 1344-1351, 2010b.
12. Fidias, P.M., S.R. Dakhil, A.P. Lyss, D.M. Loesch, D.M. Waterhouse, J.L. Bromund, R. Chen, M. Hristova-Kazmierski, J. Treat, C.K. Obasaju, M. Marciniak, J. Gill and J.H. Schiller. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. 27: 591-598, 2009.
13. Gervais, R., J.D. Hainsworth, N. Blais, B. Besse, J. Laskin, J.T. Hamm, A. Lipton, K.S. Albain, G.A. Masters, R.B. Natale, P. Selaru, S.T. Kim, R.C. Chao and R.D. Page. Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer. Lung Cancer 74: 474-480, 2011.
14. Gridelli, C., P. Maione, A. Rossi, M.L. Ferrara, M.A. Bareschino, C. Schettino, P.C. Sacco and F. Ciardiello. Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line? Oncologist 14: 137-147, 2009.
15. Gridelli, C., F. de Marinis, M. Di Maio, A. Ardizzoni, C.P. Belani, F. Cappuzzo, F. Ciardiello, P. Fidias, L. Paz-Ares, F. Perrone, R. Pirker, L. De Petris and R. Stahel. Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology. Lung Cancer 76: 269-279, 2012.
16. Grothey, A., M.M. Sugrue, D.M. Purdie, W. Dong, D. Sargent, E. Hedrick and M. Kozloff. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J. Clin. Oncol. 26: 5326-5334, 2008.
17. Hanna, N., F.A. Shepherd, F.V. Fossella, J.R. Pereira, F. De Marinis, J. von Pawel, U. Gatzemeier, T.C. Tsao, M. Pless, T. Muller, H.L. Lim, C. Desch, K. Szondy, R. Gervais, Shaharyar, C. Manegold, S. Paul, P. Paoletti, L. Einhorn and P.A. Bunn Jr. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22: 1589-1597, 2004. (Pubitemid 41079796)
18. Her, J. Dong Ui Bo Gam. The Precious Mirror of Oriental Medicine. 1597.
19. Jahanzeb, M. Continuing trastuzumab beyond progression. J. Clin. Oncol. 27: 1935-1937, 2009.
20. Jang, H.S., S.H. Kook, Y.O. Son, J.G. Kim, Y.M. Jeon, Y.S. Jang, K.C. Choi, J. Kim, S.K. Han, K.Y. Lee, B.K. Park, N.P. Cho and J.C. Lee. Flavonoids purified from Rhus verniciflua Stokes actively inhibit cell growth and induce apoptosis in human osteosarcoma cells. Biochim. Biophys. Acta 1726: 309-316, 2005. (Pubitemid 41668540)
21. Kim, H. Herbalogy. Seoul, Young Lim Sa, 2000.
22. Kim, J.H., H.P. Kim, C.H. Jung, M.H. Hong, M.C. Hong, H.S. Bae, S.D. Lee, S.Y. Park, J.H. Park and S.G. Ko. Inhibition of cell cycle progression via p27Kip1 upregulation and apoptosis induction by an ethanol extract of Rhus verniciflua Stokes in AGS gastric cancer cells. Int. J. Mol. Med. 18: 201-208, 2006.
23. Kim, E.S., V. Hirsh, T. Mok, M.A. Socinski, R. Gervais, Y.L. Wu, L.Y. Li, C.L. Watkins, M.V. Sellers, E.S. Lowe, Y. Sun, M.L. Liao, K. Osterlind, M. Reck, A.A. Armour, F.A. Shepherd, S.M. Lippman and J.Y. Douillard. Gefitinib versus docetaxel in previously treated non-smallcell lung cancer (INTEREST): a randomised phase III trial. Lancet 372: 1809-1818, 2008a.
24. Kim, J.H., H.Y. Go, D.H. Jin, H.P. Kim, M.H. Hong, W.Y. Chung, J.H. Park, J.B. Jang, H. Jung, Y.C. Shin, S.H. Kim and S.G. Ko. Inhibition of the PI3K-Akt/PKB survival pathway enhanced an ethanol extract of Rhus verniciflua Stokes-induced apoptosis via a mitochondrial pathway in AGS gastric cancer cell lines. Cancer Lett. 265: 197-205, 2008b.
25. Kim, J.H., C.H. Jung, B.H. Jang, H.Y. Go, J.H. Park, Y.K. Choi, S.I. Hong, Y.C. Shin and S.G. Ko. Selective cytotoxic effects on human cancer cell lines of phenolic-rich ethyl-acetate fraction from Rhus verniciflua Stokes. Am. J. Chin. Med. 37: 609-620, 2009.
26. Lee, J.C., J. Kim and Y.S. Jang. Ethanol-eluted extract of Rhus verniciflua stokes inhibits cell growth and induces apoptosis in human lymphoma cells. J. Biochem. Mol. Biol. 36: 337-343, 2003. (Pubitemid 37100922)
27. Lee, S.H., W.C. Choi and S.W. Yoon. Impact of standardized Rhus verniciflua stokes extract as complementary therapy on metastatic colorectal cancer: a Korean single-center experience. Integr. Cancer Ther. 8: 148-152, 2009a.
28. Lee, S.H., K.S. Kim, W.C. Choi and S.W. Yoon. Successful outcome of advanced pulmonary adenocarcinoma with malignant pleural effusion by the standardized Rhus verniciflua stokes extract: a case study. Explore (NY) 5: 242-244, 2009b.
29. Lee, S.H., W.C. Choi, K.S. Kim, J.W. Park and S.W. Yoon. Shrinkage of gastric cancer in an elderly patient who received Rhus verniciflua Stokes extract. J. Altern. Complement. Med. 16: 497-500, 2010a.
30. Lee, S.K., H.S. Jung, W.K. Eo, S.Y. Lee, S.H. Kim and B.S. Shim. Rhus verniciflua Stokes extract as a potential option for treatment of metastatic renal cell carcinoma: report of two cases. Ann. Oncol. 21: 1383-1385, 2010b.
31. Lee, S.H., K.S. Kim, H.S. Jung, S.H. Cheon, S. Kim, W.K. Eo and W.C. Choi. Efficacy and safety of standardized allergen-removed Rhus verniciflua Stokes extract in patients with advanced or metastatic pancreatic cancer: a Korean single-center experience. Oncology 81: 312-318, 2011.
32. Moon, G., S.H. Lee and J.H. Park. Effect of allergen removed Rhus verniciflua extract on inhibition of tumor metastasis. J. Korean Tradit. Oncol. 15: 47-61, 2010.
33. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J. Clin. Oncol. 26: 4617-4625, 2008.
34. Patel, J.D., T.A. Hensing, A. Rademaker, E.M. Hart, M.G. Blum, D.T. Milton and P.D. Bonomi. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 27: 3284-3289, 2009.
35. Paz-Ares, L., F. de Marinis, M. Dediu, M. Thomas, J.L. Pujol, P. Bidoli, O. Molinier, T.P. Sahoo, E. Laack, M. Reck, J. Corral, S. Melemed, W. John, N. Chouaki, A.H. Zimmermann, C. Visseren-Grul and C. Gridelli. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a doubleblind, phase 3, randomised controlled trial. Lancet Oncol. 13: 247-255, 2012.
36. Perol, M., C. Chouaid, D. Perol, F. Barlesi, R. Gervais, V. Westeel, J. Crequit, H. Lena, A. Vergnenegre, G. Zalcman, I. Monnet, H. Le Caer, P. Fournel, L. Falchero, M. Poudenx, F. Vaylet, C. Segura-Ferlay, M. Devouassoux- Shisheboran, M. Taron and B. Milleron. Randomized, Phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 30: 3516-3524, 2012.
37. Pfister, D.G., D.H. Johnson, C.G. Azzoli, W. Sause, T.J. Smith, S. Baker Jr., J. Olak, D. Stover, J.R. Strawn, A.T. Turrisi and M.R. Somerfield. American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J. Clin. Oncol. 22: 330-353, 2004. (Pubitemid 41095099)
38. Pino, M.S., T. Gamucci, G. Mansueto, T. Trapasso, F. Narducci, M.A. Giampaolo, A.M. Fariello, I. Sperduti, A. Ceribelli and F. Cognetti. A phase II study of biweekly paclitaxel (P) and gemcitabine (G), followed by maintenance weekly paclitaxel in elderly patients with advanced non-small-cell lung cancer (NSCLC). Lung Cancer 60: 381-386, 2008.
39. Pirker, R., J.R. Pereira, A. Szczesna, J. von Pawel, M. Krzakowski, R. Ramlau, I. Vynnychenko, K. Park, C.T. Yu, V. Ganul, J.K. Roh, E. Bajetta, K. O'Byrne, F. de Marinis, W. Eberhardt, T. Goddemeier, M. Emig and U. Gatzemeier. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373: 1525-1531, 2009.
40. Powell, S.M. and D.K. Barrett. An outbreak of contact dermatitis from Rhus verniciflua (Toxicodendron vernicifluum). Contact Dermatitis 14: 288-289, 1986. (Pubitemid 16060970)
41. Reck, M., J. von Pawel, P. Zatloukal, R. Ramlau, V. Gorbounova, V. Hirsh, N. Leighl, J. Mezger, V. Archer, N. Moore and C. Manegold. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J. Clin. Oncol. 27: 1227-1234, 2009.
42. Sandler, A., R. Gray, M.C. Perry, J. Brahmer, J.H. Schiller, A. Dowlati, R. Lilenbaum and D.H. Johnson. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355: 2542-2550, 2006. (Pubitemid 44917502)
43. Scagliotti, G.V., P. Parikh, J. von Pawel, B. Biesma, J. Vansteenkiste, C. Manegold, P. Serwatowski, U. Gatzemeier, R. Digumarti, M. Zukin, J.S. Lee, A. Mellemgaard, K. Park, S. Patil, J. Rolski, T. Goksel, F. de Marinis, L. Simms, K.P. Sugarman and D. Gandara. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 26: 3543-3551, 2008.
44. Schiller, J.H., D. Harrington, C.P. Belani, C. Langer, A. Sandler, J. Krook, J. Zhu and D.H. Johnson. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346: 92-98, 2002. (Pubitemid 34438899)
45. Shepherd, F.A., J. Dancey, R. Ramlau, K. Mattson, R. Gralla, M. O'Rourke, N. Levitan, L. Gressot, M. Vincent, R. Burkes, S. Coughlin, Y. Kim and J. Berille. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18: 2095-2103, 2000. (Pubitemid 30324363)
46. Shepherd, F.A., J. Rodrigues Pereira, T. Ciuleanu, E.H. Tan, V. Hirsh, S. Thongprasert, D. Campos, S. Maoleekoonpiroj, M. Smylie, R. Martins, M. van Kooten, M. Dediu, B. Findlay, D. Tu, D. Johnston, A. Bezjak, G. Clark, P. Santabarbara and L. Seymour. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353: 123-132, 2005. (Pubitemid 41058344)
47. Sminova, Z., W.C. Choi, I. Kubasova and A. Baryshnikov. Antitumor efficacy of the allergenremoved extract (ACM909Q) in Rhus verniciflua. Eur. J. Pharm. Sci. 17: 78-79, 2002.
48. Socinski, M.A., M.J. Schell, A. Peterman, K. Bakri, S. Yates, R. Gitten, P. Lee, J. Unger, J.H. Lee, M. Tynan, M. Moore and M.S. Kies. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV nonsmall-cell lung cancer. J. Clin. Oncol. 20: 1335-1343, 2002. (Pubitemid 34182817)
49. Thatcher, N., A. Chang, P. Parikh, J. Rodrigues Pereira, T. Ciuleanu, J. von Pawel, S. Thongprasert, E.H. Tan, K. Pemberton, V. Archer and K. Carroll. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366: 1527-1537, 2005. (Pubitemid 41540110)
50. Therasse, P., S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, L. Rubinstein, J. Verweij, M. Van Glabbeke, A.T. van Oosterom, M.C. Christian and S.G. Gwyther. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92: 205-216, 2000.
51. Zhang, L., S. Ma, X. Song, B. Han, Y. Cheng, C. Huang, S. Yang, X. Liu, Y. Liu, S. Lu, J. Wang, S. Zhang, C. Zhou, X. Zhang, N. Hayashi and M. Wang. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol. 13: 466-475, 2012.